| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
H-Orn(TFA)-OH does not have a defined pharmacological target; its primary role is as a synthetic intermediate. Upon deprotection, ornithine interacts with amino acid transporters, particularly the cationic amino acid transporter (CAT) family, and with enzymes of the urea cycle such as ornithine transcarbamylase and ornithine decarboxylase. It may also affect polyamine synthesis pathways.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies on ornithine derivatives show they can influence cellular metabolism, polyamine production, and nitric oxide synthesis. Ornithine is a precursor for arginine and polyamines, affecting cell proliferation and differentiation. The TFA-protected form is generally inactive until deprotected, but it serves as a useful tool for controlled release studies in cell culture. |
| ln Vivo |
In vivo studies on ornithine derivatives are limited. Ornithine itself has been studied for its role in ammonia detoxification and wound healing. However, H-Orn(TFA)-OH specifically has little published in vivo data, as it is primarily used as a synthetic intermediate rather than a bioactive agent.
|
| Enzyme Assay |
In vitro enzyme assays for ornithine derivatives typically measure interactions with ornithine decarboxylase or arginase. A standard protocol involves incubating the compound with the enzyme in Tris-HCl buffer (pH 7.4) at 37°C, and product formation (putrescine or urea) is quantified by HPLC or colorimetric methods. For transporter binding, radiolabeled competition assays using cell membrane preparations are employed.
|
| Cell Assay |
In vitro cellular assays use cell lines such as HepG2 or primary hepatocytes. Cells are seeded in 96-well plates and treated with H-Orn(TFA)-OH at concentrations of 1-1000 µM for 24-72 hours. Viability is assessed by MTT, and metabolic effects (e.g., polyamine levels) are measured by ELISA or HPLC. Gene expression of ornithine-related enzymes is analyzed by qPCR.
|
| Animal Protocol |
In vivo animal studies with ornithine derivatives typically involve oral or intraperitoneal administration to rodents at doses of 50-500 mg/kg. Blood and tissue samples are collected for analysis of amino acid levels and metabolic markers. However, for the TFA-protected form, specific studies are scarce; most data come from unprotected ornithine.
|
| ADME/Pharmacokinetics |
H-Orn(TFA)-OH (MW ~242.15 g/mol) is a polar molecule with good aqueous solubility. The TFA group is cleaved by esterases or under basic conditions. Following absorption, it distributes via amino acid transporters and is metabolized through urea cycle pathways, with renal excretion.
|
| Toxicity/Toxicokinetics |
The compound exhibits low toxicity, consistent with amino acid derivatives. Acute oral LD₅₀ in rodents is expected >2000 mg/kg. It is not genotoxic or carcinogenic. Standard lab precautions should be taken; skin and eye irritation may occur.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
H-Orn(TFA)-OH is a white solid with ≥98% purity. Store at -20°C as powder. For research use only, not for human therapy. It is commonly used in peptide synthesis and metabolic studies.
|
| Molecular Formula |
C5H11NO2.HCL
|
|---|---|
| Molecular Weight |
153.60728
|
| Exact Mass |
153.055
|
| CAS # |
52605-49-9
|
| PubChem CID |
171173
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
138.6ºC at 760 mmHg
|
| Melting Point |
~125 °C
|
| Flash Point |
37.6ºC
|
| LogP |
0.961
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
9
|
| Complexity |
72.8
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(=O)CNC.Cl
|
| InChi Key |
NIDZUMSLERGAON-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H11NO2.ClH/c1-3-8-5(7)4-6-2;/h6H,3-4H2,1-2H3;1H
|
| Chemical Name |
ethyl 2-(methylamino)acetate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5100 mL | 32.5500 mL | 65.0999 mL | |
| 5 mM | 1.3020 mL | 6.5100 mL | 13.0200 mL | |
| 10 mM | 0.6510 mL | 3.2550 mL | 6.5100 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
